Integrating Continuous Glucose Monitor Data Directly into the Electronic Health Record: Proof of Concept.

abstract：BACKGROUND:Recent evidence emphasizes the importance of maintaining normoglycemia in critically ill patients to reduce morbidity and mortality. Different analytical methods of varying accuracy exist for obtaining and measuring blood glucose in critically ill patients. The purpose of this study was to determine if there...

journal_title：Diabetes technology & therapeutics

authors： Slater-MacLean L,Cembrowski G,Chin D,Shalapay C,Binette T,Hegadoren K,Newburn-Cook C

更新日期：2008-06-01 00:00:00

abstract：BACKGROUND:The aim of this investigation was to assess clinical predictors of the glycosylated hemoglobin (HbA1C) response after the addition of a thiazolidinedione (TZD) to a biguanide, a sulfonylurea, or both in subjects with type 2 diabetes. METHODS:Chart review (n = 68 physicians) was used to identify consecutive ...

journal_title：Diabetes technology & therapeutics

authors： Izumi R,Hurt J,Maki KC,Bell M,Zavras AI,McCamish M

更新日期：2007-12-01 00:00:00

abstract：: Background: This observational study investigated whether the connected NovoPen® 6 could influence insulin regimen management and glycemic control in people with type 1 diabetes (T1D) using a basal-bolus insulin regimen and continuous glucose monitoring in a real-world set...

journal_title：Diabetes technology & therapeutics

authors： Adolfsson P,Hartvig NV,Kaas A,Møller JB,Hellman J

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:Real-time continuous glucose monitoring (CGM) was studied in 140 adults with diabetes over a 12-week period of home use. Hemoglobin A(1c)(HbA1c) was measured on day 1 (baseline) and at weeks 6 and 12. METHODS:On day 1, participants received the CGM device (STS(R) System, DexCom, Inc., San Diego, CA) and und...

journal_title：Diabetes technology & therapeutics

authors： Bailey TS,Zisser HC,Garg SK

更新日期：2007-06-01 00:00:00

abstract：OBJECTIVE:This study assessed the association of serum adiponectin with carotid intimal medial thickness (IMT) in Asian Indians with different grades of glucose intolerance. METHODS:Subjects with normal glucose tolerance (NGT) (n = 520), impaired glucose tolerance (IGT) (n = 115), and type 2 diabetes mellitus (T2DM) (...

journal_title：Diabetes technology & therapeutics

authors： Gokulakrishnan K,Indulekha K,Ganesan S,Anuradha S,Mohan V

更新日期：2010-02-01 00:00:00

abstract：BACKGROUND:Previous studies of aerobic exercise have found lower sensor accuracy during exercise. Whether or not resistance exercise would also be associated with lower sensor accuracy has not yet been examined. This study sought to investigate the accuracy of continuous glucose monitoring sensor values at rest, during...

journal_title：Diabetes technology & therapeutics

authors： Yardley JE,Sigal RJ,Kenny GP,Riddell MC,Lovblom LE,Perkins BA

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:This study was designed to assess the accuracy, reliability, and contribution to clinical decision-making of two commercially available continuous glucose monitoring (CGM) devices using a novel analytical approach. STUDY DESIGN:Eleven individuals with type 1 diabetes and five with type 2 diabetes wore a Gua...

journal_title：Diabetes technology & therapeutics

authors： Mazze RS,Strock E,Borgman S,Wesley D,Stout P,Racchini J

更新日期：2009-01-01 00:00:00

abstract：:Chronic hyperglycemia, as assessed by hemoglobin A1c (HbA1c) levels, has been associated with the development of microvascular and macrovascular complications of diabetes. Several studies have shown that acute hyperglycemia can add to the effect of chronic hyperglycemia in inducing tissue damage. Acute hyperglycemia c...

journal_title：Diabetes technology & therapeutics

authors： Marcovecchio ML,Lucantoni M,Chiarelli F

更新日期：2011-03-01 00:00:00

abstract：: Aims: We evaluated the real-life efficacy and safety of empagliflozin in combination with optimized insulin therapy in patients with type 1 diabetes (T1D). Methods: This was a prospective study, including 27 patients with T1D t...

journal_title：Diabetes technology & therapeutics

authors： Bayona Cebada A,Nattero-Chávez L,Alonso Díaz S,Escobar-Morreale HF,Luque-Ramírez M

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:Programmable and fixed auditory and/or vibratory threshold alerts are essential features of real-time continuous glucose monitoring (rtCGM) systems that provide users time to intervene before the onset of clinical hypoglycemia or hyperglycemia. A sixth-generation rtCGM system from Dexcom, Inc. (G6) includes ...

journal_title：Diabetes technology & therapeutics

authors： Puhr S,Derdzinski M,Welsh JB,Parker AS,Walker T,Price DA

更新日期：2019-04-01 00:00:00

abstract：:The Editor of Diabetes Technology & Therapeutics is officially retracting the article entitled, "No Deleterious Effect of Lockdown Due to COVID-19 Pandemic on Glycaemic Control, Measured by Glucose Monitoring, in Adults with Type 1 Diabetes," by Beato-Vibora PI. Diabetes Technol Ther 2020; epub DOI: 10.1089/dia.2020.0...

journal_title：Diabetes technology & therapeutics

authors： Beato-Víbora PI

更新日期：2020-05-12 00:00:00

abstract：:Use of the Medtronic MiniMed Continuous Glucose Monitoring System (CGMS) in non-diabetic children has revealed many low and high sensor glucose (SG) values, suggesting that the original analytical algorithm (Solutions 2.0) might be overreading glycemic excursions. A revised algorithm (Solutions 3.0) was introduced in ...

journal_title：Diabetes technology & therapeutics

authors： Weinzimer SA,DeLucia MC,Boland EA,Steffen A,Tamborlane WV

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Glucose monitoring based on sampling skin interstitial fluid (ISF) is being developed as an alternative to fingerstick blood glucose monitoring. Time delays between rapidly changing levels of glucose in blood and interstitial fluid have been reported in the literature to be between 5 and 20 minutes. This stu...

journal_title：Diabetes technology & therapeutics

authors： Smith A,Yang D,Delcher H,Eppstein J,Williams D,Wilkes S

更新日期：1999-04-01 00:00:00

abstract：BACKGROUND:Faster aspart is insulin aspart (IAsp) in a new formulation, which in continuous subcutaneous insulin infusion (CSII) in subjects with type 1 diabetes has shown a faster onset and offset of glucose-lowering effect than IAsp. METHODS:This double-blind, randomized, crossover active-controlled trial compared 2...

journal_title：Diabetes technology & therapeutics

authors： Bode BW,Johnson JA,Hyveled L,Tamer SC,Demissie M

更新日期：2017-01-01 00:00:00

abstract：OBJECTIVE:To evaluate the safety of in-home use of the MiniMed™ 670G system with SmartGuard™ technology in children with type 1 diabetes (T1D). METHODS:Participants (N = 105, ages 7-13 years, mean age 10.8 ± 1.8 years) were enrolled at nine centers (eight in the United States and one in Israel) and completed a 2-week ...

journal_title：Diabetes technology & therapeutics

authors： Forlenza GP,Pinhas-Hamiel O,Liljenquist DR,Shulman DI,Bailey TS,Bode BW,Wood MA,Buckingham BA,Kaiserman KB,Shin J,Huang S,Lee SW,Kaufman FR

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:We evaluated the impact of a 2-year chat line involving adolescents with type 1 diabetes regarding quality of life and metabolic control. METHODS:We enrolled 193 children, 10-18 years of age (mean ± SD, 13.6 ± 2.7 years), with type 1 diabetes for 1.2-6 years (3.6 ± 2.4 years), body mass index of 23.2 ± 4.1 ...

journal_title：Diabetes technology & therapeutics

authors： Iafusco D,Galderisi A,Nocerino I,Cocca A,Zuccotti G,Prisco F,Scaramuzza A

更新日期：2011-05-01 00:00:00

abstract：INTRODUCTION:The ProAct study has shown that a pump switch to the Accu-Chek(®) Combo system (Roche Diagnostics Deutschland GmbH, Mannheim, Germany) in type 1 diabetes patients results in stable glycemic control with significant improvements in glycated hemoglobin (HbA1c) in patients with unsatisfactory baseline HbA1c a...

journal_title：Diabetes technology & therapeutics

authors： Pfützner A,Weissmann J,Mougiakakou S,Daskalaki E,Weis N,Ziegler R

更新日期：2015-06-01 00:00:00

abstract：BACKGROUND:We aimed to assess the effect of continuous subcutaneous insulin infusion (CSII) therapy in patients with "recalcitrant diabetes" whose glycemia had not been controlled adequately with multiple daily injections of insulin or insulin plus oral hypoglycemic agents. PATIENTS AND METHODS:We retrospectively anal...

journal_title：Diabetes technology & therapeutics

authors： Sudhakaran C,Anjana RM,Rao K,Unnikrishnan R 1st,Suresh T,Mohan V

更新日期：2009-11-01 00:00:00

abstract：OBJECTIVE:This study was designed to assess whether waist circumference can predict metabolic syndrome abnormalities in primary schoolchildren. RESEARCH DESIGN AND METHODS:Of 5,103 children (2,526 males) 4-13 years old who underwent anthropometric measurements, 530 had more extensive testing. Body mass index (BMI), wa...

journal_title：Diabetes technology & therapeutics

authors： Hirschler V,Maccallini G,Calcagno M,Aranda C,Jadzinsky M

更新日期：2007-04-01 00:00:00

abstract：:The increasing prevalence of type 1 and type 2 diabetes mellitus combined with advancement in early detection of cardiovascular disease (CVD) has placed CVD as a significant concern for preventative pediatric medicine. The public health burden of type 2 diabetes is predicted to parallel increasing obesity in children ...

journal_title：Diabetes technology & therapeutics

authors： Truong UT,Maahs DM,Daniels SR

更新日期：2012-06-01 00:00:00

abstract：:Several biopharmaceuticals, including insulin and insulin analogs, are, or shortly will be, off-patent, thereby providing an opportunity for companies to attempt to manufacture "copies" commonly referred to as biosimilars and also known as follow-on biologics. Reassurance that such copy biologics are equally safe and ...

journal_title：Diabetes technology & therapeutics

authors： Owens DR,Landgraf W,Schmidt A,Bretzel RG,Kuhlmann MK

更新日期：2012-11-01 00:00:00

abstract：BACKGROUND:Because strict glucose control is important for reducing the complications of diabetes, the self-monitoring of blood glucose is one of the fundamental treatment modalities. Many glucometers have been developed. In the present study, we evaluated a new glucometer: GlucoDr Plus (Allmedicus, Anyang, Gyeonggi-do...

journal_title：Diabetes technology & therapeutics

authors： Ko DH,Lim S,Song SH,Choi SH,Park YJ,Park KU,Jang HC,Song J

更新日期：2010-04-01 00:00:00

abstract：BACKGROUND:The efficacy of short-term professional continuous glucose monitoring (CGM) for glycemic control in patients with diabetes remains unclear. METHODS:We performed a 3-month study to evaluate the benefits of CGM in 64 patients. RESULTS:The overall glycemic control of patients who underwent CGM improved signif...

journal_title：Diabetes technology & therapeutics

authors： Shibusawa R,Yamada E,Okada S,Nakajima Y,Bastie CC,Yamada M

更新日期：2018-09-01 00:00:00

abstract：:Diabetic nephropathy is one of the major causes of end-stage renal disease and is often associated with other macrovascular complications such as ischemic heart disease and peripheral vascular disease. Angiotensin converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (AIIR) have both been shown to ...

journal_title：Diabetes technology & therapeutics

authors： Boner G,Cao Z,Cooper ME

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Drugs with unspecific stimulating effects on beta-cell secretion increase the homeostasis model assessment (HOMA)-B score, indicating improved beta-cell "function." We investigated whether the beta-cell protection provided by adding pioglitazone (PIO) to glimepiride (GLIM) in comparison to up-titrating the G...

journal_title：Diabetes technology & therapeutics

authors： Pfützner A,Derwahl M,Jacob S,Hohberg C,Blümner E,Lehmann U,Fuchs W,Forst T

更新日期：2010-08-01 00:00:00

abstract：BACKGROUND:The OpT2mise randomized trial was designed to compare the effects of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) on glucose profiles in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS:Patients with glycated hemoglobin (HbA1c) levels of ≥8% (64 mmol/mol) and...

journal_title：Diabetes technology & therapeutics

authors： Conget I,Castaneda J,Petrovski G,Guerci B,Racault AS,Reznik Y,Cohen O,Runzis S,de Portu S,Aronson R,OpT2mise Study Group.

更新日期：2016-01-01 00:00:00

abstract：:Disease registries are a searchable list of all patients with a particular chronic condition that often interface with an electronic medical record. The well-designed registry links all members of the patient's health team and provides key information for patients and physicians. The critical impact of a registry is t...

journal_title：Diabetes technology & therapeutics

authors： Khan L,Mincemoyer S,Gabbay RA

更新日期：2009-04-01 00:00:00

abstract：BACKGROUND:Implanted insulin pumps using the peritoneal route provide long-term improvement of glucose control compared with subcutaneous insulin therapy in type 1 diabetes (T1D) patients. The stability of insulin preparation is critical for a safe use in implanted pumps. Insuman implantable(®) (400 IU/mL) (Sanofi-Aven...

journal_title：Diabetes technology & therapeutics

authors： Schaepelynck P,Riveline JP,Renard E,Hanaire H,Guerci B,Baillot-Rudoni S,Sola-Gazagnes A,Catargi B,Fontaine P,Millot L,Martin JF,Tachouaft H,Jeandidier N,EVADIAC Group.

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:Continuous glucose monitoring (CGM) time-series are often analyzed, retrospectively, to investigate glucose variability (GV), a risk factor for the development of complications in type 1 diabetes (T1D). In the literature, several tens of different indices for GV quantification have been proposed, but many of...

journal_title：Diabetes technology & therapeutics

authors： Fabris C,Facchinetti A,Sparacino G,Zanon M,Guerra S,Maran A,Cobelli C

更新日期：2014-10-01 00:00:00

abstract：:The World Wide Web now hosts a multitude of diabetes educational materials in various formats. Of particular interest is the diabetes/insulin tutorial available at the AIDA Website (accessible directly at: www.2aida.info). The tutorial combines textual or "static" information with an interactive diabetes simulator-AID...

journal_title：Diabetes technology & therapeutics

authors： Reed K,Lehmann ED

更新日期：2006-02-01 00:00:00